Belite Bio Inc - יחס שווי כולל של החברה להכנסות BLTE

סמלים רשמיים של חברת belitebio.com (BLTE)

Belite Bio, Inc (BLTE) is an innovative developer of therapies to combat Stargardt disease, positioning itself for leadership in the ophthalmology segment. The Enterprise Value to revenue ratio reflects market expectations, with the current level standing at 0.00. The company's strategy focuses on treating rare retinal pathologies, implementing a revolutionary oral method to halt blindness to meet high patient demand.

BLTE (Belite Bio) היסטוריית מכפיל EV/Sales מ-23.11.2025 עד 20.11.2026

Belite Bio Inc - פילוחים אנליטיים ומדדי מפתח (BLTE)

- שער מניה ותחזית מחירי מומחים:
הערכת שווי פונדמנטלית של החברה:BLTE (Belite Bio, Inc)
דוגמת מוצר של Belite Bio, Inc.

This ratio compares the total enterprise value, including debt and cash, to the volume of generated revenue, allowing for an assessment of the market value of each unit of income. By analyzing historical EV/Sales trends, an investor can determine the degree to which an asset is overbought, which is particularly critical for Belite Bio, Inc (BLTE), as its clinical-stage biotech startup model excludes the influence of industrial production.